284 related articles for article (PubMed ID: 26754662)
21. Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma.
Kwon H; Kim WG; Sung TY; Jeon MJ; Song DE; Lee YM; Yoon JH; Chung KW; Hong SJ; Baek JH; Lee JH; Kim TY; Shong YK; Kim WB
J Surg Oncol; 2016 Feb; 113(2):152-8. PubMed ID: 26799259
[TBL] [Abstract][Full Text] [Related]
22. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.
Fanget F; Demarchi MS; Maillard L; Lintis A; Decaussin M; Lifante JC
Br J Surg; 2021 Sep; 108(9):1064-1071. PubMed ID: 33899100
[TBL] [Abstract][Full Text] [Related]
23. Presymptomatic thyroidectomy in multiple endocrine neoplasia 2a.
Heizmann O; Haecker FM; Zumsteg U; Müller B; Oberholzer M; Oertli D
Eur J Surg Oncol; 2006 Feb; 32(1):98-102. PubMed ID: 16325365
[TBL] [Abstract][Full Text] [Related]
24. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
[TBL] [Abstract][Full Text] [Related]
25. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
Łacka K; Michałek K; Majewski P
Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.
Rozenblat T; Hirsch D; Robenshtok E; Grozinsky-Glasberg S; Gross DJ; Mazeh H; Benbassat C; Twito O; Levy S; Mizrachi A; Shpitzer T; Bachar G
Eur J Surg Oncol; 2020 Nov; 46(11):2023-2028. PubMed ID: 32389525
[TBL] [Abstract][Full Text] [Related]
27. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).
Cohen R; Campos JM; Salaün C; Heshmati HM; Kraimps JL; Proye C; Sarfati E; Henry JF; Niccoli-Sire P; Modigliani E
J Clin Endocrinol Metab; 2000 Feb; 85(2):919-22. PubMed ID: 10690910
[TBL] [Abstract][Full Text] [Related]
28. Temporal Trends in the Presentation, Treatment, and Outcome of Medullary Thyroid Carcinoma: An Israeli Multicenter Study.
Hirsch D; Twito O; Levy S; Bachar G; Robenshtok E; Gross DJ; Mazeh H; Benbassat C; Grozinsky-Glasberg S
Thyroid; 2018 Mar; 28(3):369-376. PubMed ID: 29402183
[TBL] [Abstract][Full Text] [Related]
29. Medullary Thyroid Carcinoma: Prognostic Variables And Tumour Markers Affecting Survival.
Hassan A; Siddique M; Riaz S; Khan AI; Nawaz MK; Bashir H
J Ayub Med Coll Abbottabad; 2018; 30(Suppl 1)(4):S627-S632. PubMed ID: 30838820
[TBL] [Abstract][Full Text] [Related]
30. Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.
Yip DT; Hassan M; Pazaitou-Panayiotou K; Ruan DT; Gawande AA; Gaz RD; Moore FD; Hodin RA; Stephen AE; Sadow PM; Daniels GH; Randolph GW; Parangi S; Lubitz CC
Surgery; 2011 Dec; 150(6):1168-77. PubMed ID: 22136837
[TBL] [Abstract][Full Text] [Related]
31. Dynamic Risk Stratification in the Follow-Up of Children and Adolescents with Differentiated Thyroid Cancer.
Zanella AB; Scheffel RS; Nava CF; Golbert L; Laurini de Souza Meyer E; Punales M; Gonçalves I; Dora JM; Maia AL
Thyroid; 2018 Oct; 28(10):1285-1292. PubMed ID: 30129889
[TBL] [Abstract][Full Text] [Related]
32. A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal.
Faggiano A; Milone F; Ramundo V; Chiofalo MG; Ventre I; Giannattasio R; Severino R; Lombardi G; Colao A; Pezzullo L
J Clin Endocrinol Metab; 2010 Sep; 95(9):E32-6. PubMed ID: 20534767
[TBL] [Abstract][Full Text] [Related]
33. Ultrasonographic Features of Medullary Thyroid Carcinoma: Do they Correlate with Pre and PostOperative Calcitonin Levels?
Cho KE; Gweon HM; Park AY; Yoo MR; Kim J; Youk JH; Park YM; Son EJ
Asian Pac J Cancer Prev; 2016; 17(7):3357-62. PubMed ID: 27509975
[TBL] [Abstract][Full Text] [Related]
34. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.
Pelizzo MR; Boschin IM; Bernante P; Toniato A; Piotto A; Pagetta C; Nibale O; Rampin L; Muzzio PC; Rubello D
Eur J Surg Oncol; 2007 May; 33(4):493-7. PubMed ID: 17125960
[TBL] [Abstract][Full Text] [Related]
35. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
36. Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer.
Machens A; Lorenz K; Dralle H
Br J Surg; 2019 Mar; 106(4):412-418. PubMed ID: 30725475
[TBL] [Abstract][Full Text] [Related]
37. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin.
Mirallié E; Iacobone M; Sebag F; Henry JF
Eur J Surg Oncol; 2004 Sep; 30(7):790-5. PubMed ID: 15296996
[TBL] [Abstract][Full Text] [Related]
38. An Undetectable Postoperative Calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study.
Duval MADS; Ferreira CV; Marmitt L; Dora JM; Espíndola M; Benini AF; Camelier MV; Bulzico D; Andrade FA; Alves Júnior PA; Corbo R; Vaisman F; Zanella AB; Scheffel RS; Maia AL
Thyroid; 2023 Jan; 33(1):82-90. PubMed ID: 36222615
[No Abstract] [Full Text] [Related]
39. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas.
Weber T; Schilling T; Frank-Raue K; Colombo-Benkmann M; Hinz U; Ziegler R; Klar E
Surgery; 2001 Dec; 130(6):1044-9. PubMed ID: 11742336
[TBL] [Abstract][Full Text] [Related]
40. Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.
Kim TH; Ki CS; Kim HS; Kim K; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim SW; Chung JH
J Clin Endocrinol Metab; 2017 May; 102(5):1757-1764. PubMed ID: 28323925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
